Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Melinta enters financing agreement with Oberland Capital

Executive Summary

Infectious disease-focused Melinta Therapeutics Inc. entered into a loan and securities financing agreement with Oberland Capital Management in which Melinta is eligible to receive up to $90mm in equity and debt. Most of the funding was received upon the recent FDA approval of the NDAs for Baxdela (delafloxacin) in treating acute bacterial skin and skin structure infections. The company can draw down funds in three additional tranches. Melinta will use the funds to commercialize Baxdela.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
Deal Status
  • Final
Deal Type
  • Financing
    • Nonconvertible Debt
    • Private Placement

Related Companies